Source: International Congress 2018 – On the right path: understanding and improving the function of an overloaded right heart ventricle
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Liu Shiu Cheong (Dundee, United Kingdom), B. Lipworth (Dundee, United Kingdom), J. Weir-Mccall (Vancouver, Canada), A. Struthers (Dundee, United Kingdom). Allopurinol reduces RV mass in patients with severe COPD. 1635

Member's Comments

No comment yet.

Related content which might interest you: Low body mass index in hospitalised patients with chronic obstructive pulmonary disease (COPD): is related to low lung function and increased mortality Source: Eur Respir J 2006; 28: Suppl. 50, 66s Year: 2006 Resistin, 8-isorpostanes and stress right ventricular diastolic dysfunction -   predictors for exacerbations in non-severe chronic obstructive pulmonary disease patients Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 NT-proBNP accurately reflects the impact of severe COPD exacerbation on the right ventricle (RV) Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations Year: 2013 ²DOSE² index in severe COPD Source: Eur Respir J 2007; 30: Suppl. 51, 97s Year: 2007 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 How to prevent exercise-induced hypoxemia in patients with severe COPD? Source: Annual Congress 2008 - Use of noninvasive ventilation in various conditions Year: 2008 Effect of long-term therapy with short-acting β2-agonist on left ventricle systolic function in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 14s Year: 2004 Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Effect of erdosteine in moderately severe COPD patients Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Fat-free mass depletion and functional exercise capacity in COPD patients Source: Annual Congress 2007 - Predicting factors of patients undergoing rehabilitation Year: 2007 Is there benefit from proactive case-detection of left ventricular systolic dysfunction (LVSD) using BNP in patients with advanced COPD? Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Τhe influence of pulmonary disease on ventricular diastolic dysfunction in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 539s Year: 2003 Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Mitochondrial dysfunction in COPD patients with low body mass index Source: Eur Respir J 2007; 30: 600 Year: 2007 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Effects of nebivolol and ivabradine on the left ventricular diastolic function in patients (pts) with COPD and stable angina Source: International Congress 2014 – COPD markers Year: 2014 Does lung volume reduction surgery improve chronotropic incompetence in chronic obstructive pulmonary disease (COPD) patients? Source: Annual Congress 2011 - Pleural diseases and pneumothorax Year: 2011 Right heart function and hypoxemia in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 64s Year: 2005 Rating predominance of pulmonary hypertension, lung hyperinflation and left ventricular dysfunction in patients with moderate and severe COPD in Belarus Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Pulmonary hypertension and right ventricular impairment in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 59s Year: 2004